Exelixis, Inc. (NASDAQ:EXEL) Director Sells $694,600.75 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Bob Oliver sold 18,647 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the transaction, the director now directly owns 33,514 shares of the company’s stock, valued at approximately $1,248,396.50. This trade represents a 35.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Exelixis Price Performance

EXEL stock opened at $37.65 on Friday. The business has a fifty day moving average price of $34.42 and a 200 day moving average price of $31.54. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $38.43. The stock has a market capitalization of $10.54 billion, a price-to-earnings ratio of 21.27, a P/E/G ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Coppell Advisory Solutions LLC bought a new position in Exelixis in the 4th quarter valued at $25,000. Colonial Trust Co SC boosted its position in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 765 shares during the last quarter. USA Financial Formulas bought a new position in Exelixis in the 4th quarter valued at $32,000. Principal Securities Inc. boosted its position in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. Finally, Kestra Investment Management LLC bought a new position in Exelixis in the 4th quarter valued at $39,000. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on EXEL. Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $30.00 to $40.00 in a report on Monday, January 27th. Truist Financial upped their price target on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Piper Sandler increased their target price on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Wells Fargo & Company cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 target price for the company. in a report on Monday. Finally, Guggenheim reissued a “buy” rating and issued a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.